Phase III study halted: Ferrer’s oral edaravone disappoints in ALS
Ferrer has announced that its FAB122 failed to achieve its primary efficacy and key secondary endpoints in the Phase III ADORE trial for ALS.
Ferrer has announced that its FAB122 failed to achieve its primary efficacy and key secondary endpoints in the Phase III ADORE trial for ALS.
What's Your Reaction?
